PD1 Blockade in Cancer: Impact on Myeloid Cells
- PMID: 32459997
- DOI: 10.1016/j.trecan.2020.02.018
PD1 Blockade in Cancer: Impact on Myeloid Cells
Abstract
Programmed death 1 (PD1) has emerged as a major inhibitor of antitumor T cells, and anti-PD1 therapies have demonstrated clinical efficacy in multiple cancers. However, the impact of PD1 on other immune cells had remained unclear. A recent study by Strauss et al. describes how myeloid cell-intrinsic PD1 signaling limits myelopoiesis in cancer pertinent to anti-PD1 therapies.
Keywords: PD1; T cells; antitumor immunity; dendritic cells (DCs); myeloid cells; myeloid-derived suppressor cells (MDSCs).
Copyright © 2020 Elsevier Inc. All rights reserved.
Comment on
-
Targeted deletion of PD-1 in myeloid cells induces antitumor immunity.Sci Immunol. 2020 Jan 3;5(43):eaay1863. doi: 10.1126/sciimmunol.aay1863. Sci Immunol. 2020. PMID: 31901074 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
